Prof Xavier Leleu speaks to ecancer about isatuximab subcutaneous via an on-body delivery system versus istuximab intravenous (IV), plus pomalidomide and dexamethasone, in relapsed/refractory multiple myloma.

The phase 3 IRAKLIA trial reveals that an on-body delivery system for subcutaneous cetuximab is as effective as traditional IV administration.

The study meets its primary endpoints, showing similar overall response rates and serum concentrations.

This groundbreaking approach enhances patient experience with an automated delivery device, setting a new standard for subcutaneous drug delivery and improving care for myeloma patients.